SIMCERE PHARMA (02096) and Puqi Pharmaceuticals have entered into an exclusive promotion service agreement for Pumeixiti gel.

date
19:38 01/06/2026
avatar
GMT Eight
Sinopharm Holdings (02096) announced that on June 1, 2026, the Group and Beijing Puqi Pharmaceuticals Technology Co., Ltd. (Puqi Pharmaceuticals) entered into an exclusive promotion service agreement for Pumei Sitini Gel (the Agreement). Under the Agreement, the Group will obtain exclusive promotion rights for Pumei Sitini Gel in all indications in the field of dermatology in Mainland China, Hong Kong, and Macau. Currently, the new drug application (NDA) for Pumei Sitini Gel for the indication of atopic dermatitis (AD) in adults and adolescents has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. This collaboration will further strengthen the Group's product layout in the field of autoimmune diseases.
Simcere Pharma (02096) announced that on June 1, 2026, the group entered into an exclusive promotion service agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharmaceutical) for the gel of pemetrexed. According to the agreement, the group will have exclusive promotion rights for pemetrexed gel in all indications in the field of dermatology in mainland China, Hong Kong, and Macau. Currently, the new drug application (NDA) for pemetrexed gel for the treatment of adult and adolescent atopic dermatitis (AD) has been accepted by the Center for Drug Evaluation of the National Medical Products Administration. This cooperation will further strengthen the group's product layout in the field of autoimmune diseases.